<code id='2284544C80'></code><style id='2284544C80'></style>
    • <acronym id='2284544C80'></acronym>
      <center id='2284544C80'><center id='2284544C80'><tfoot id='2284544C80'></tfoot></center><abbr id='2284544C80'><dir id='2284544C80'><tfoot id='2284544C80'></tfoot><noframes id='2284544C80'>

    • <optgroup id='2284544C80'><strike id='2284544C80'><sup id='2284544C80'></sup></strike><code id='2284544C80'></code></optgroup>
        1. <b id='2284544C80'><label id='2284544C80'><select id='2284544C80'><dt id='2284544C80'><span id='2284544C80'></span></dt></select></label></b><u id='2284544C80'></u>
          <i id='2284544C80'><strike id='2284544C80'><tt id='2284544C80'><pre id='2284544C80'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:2
          Photography of the US department of health and human services in Silver Spring MD
          Manuel Balce Ceneta/AP

          An increasing number of medical device companies are submitting fabricated and unreliable data, the Food and Drug Administration noted Tuesday morning. The data comes from third-party labs hired by device firms to test the quality of their products.

          Triple-check your data or we’ll reject your device, the FDA warned.

          advertisement

          The goal of third-party testing is to ensure a device meets the FDA’s standards in a range of areas, including biocompatibility, sterility, and mechanical performance. The agency wrote that it has noticed an uptick in false data submissions in recent years, particularly from facilities based in China and India. In some cases, the facilities will send data copied from previous device submissions.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          Readout Newsletter: Bluebird, CVS, Contineum
          Readout Newsletter: Bluebird, CVS, Contineum

          JustinSullivan/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetour

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Asahi Kasei to buy Calliditas, picking up kidney disease drug

          AdobeLONDON—Seekingtobuildupitspharmabusiness,theJapaneseconglomerateAsahiKaseiismovingtobuySwedishb